Press Release

Eckert & Ziegler Fiscal Year 2012: Sales increased. Profits remain constant.

Berlin, March 28, 2013. The Berlin company Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope applications in medicine, science and industry, increased its sales to some extent in the last business year of 2012. Consolidated sales rose EUR 3.8 million by 3% to EUR 120.0 million (previous year: EUR 116.2 million).

Broken down by the individual segments, turnover was distributed as follows: The Isotope Products segment, benefiting in particular from the USD/EUR exchange rate trend, grew by 3% to EUR 56.1 million. In the Radiation Therapy segment the continuing growth in cancer radiation equipment contributed to a rise in sales by 4% to EUR 31.8 million. The Radiopharma segment showed only a slight rise of 1% to EUR 26.0 million. The Environmental Services segment was able to increase by 12% to EUR 6.2 million thanks to a new large order.

The earnings key figures developed as follows: the EBITDA dropped to EUR 27.5 million (previous year: EUR 30.4 million) and the EBIT was reduced to EUR 19.7 million (previous year: EUR 22.9 million). The reasons for this were disproportionately high costs in the area of production (in part in the Environmental Services segment due to price-related appropriation to reserves as well as one-time expenditures in conjunction with the development of a new disposal method and the fulfillment of increased demands by the authorities) as well as in administrative costs (in part in the Isotope Products segment due to currency exchange effects as well as one-time expenditures for a large yet ultimately abandoned acquisition project). Because of lowered taxes (last year the Radiation Therapy segment received an adjustment for the inclusion of active deferred taxes) the income after taxes and minority interests almost equaled that of the previous year (EUR 10.4 million) with EUR 10.3 million. This corresponds to earnings per share of EUR 1.95 (previous year: EUR 1.98). The net liquidity, or the surplus of the means of payment above the loan debts, grew by 8% to EUR 15.4 million (previous year: EUR 14.3 million).

Altogether, for the coming business years 2013 and 2014 sales of approx. EUR 125 million or at least EUR 130 million are anticipated. These sales objectives depict the basic scenario without acquisitions. The Executive Board continues to see a realistic opportunity for higher sales marks through strategic company acquisitions. The income after taxes and minority interests should be approximately EUR 12 million in the year 2013 and over EUR 15 million in 2014.

The full version of the annual report can be accessed at:

The Executive Board and the Supervisory Board will recommend a dividend of EUR 0.60 per dividend-entitled share (previous year: EUR 0.60) at the Annual General Meeting on May 17, 2013.

With some 610 employees, the Eckert & Ziegler Group is one of the world’s largest providers of isotope-technical components for radiation therapy and nuclear medicine.

If you have any questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138,,